Trelegy Ellipta 62.5 ug/1

Trelegy Ellipta 62.5 ug/1 is a combination inhaler for respiratory conditions. It contains fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. This powder inhaler is designed for inhalation use.

Trelegy Ellipta 62.5 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is not intended for immediate relief of sudden breathing problems.

Common effects of Trelegy Ellipta 62.5 ug/1 may include throat irritation, headache, and hoarseness. Some users might experience a dry mouth or taste changes. These effects are generally mild and temporary, but persistent issues should be discussed with a healthcare provider.

Trelegy Ellipta 62.5 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as heart disease or severe asthma, should use this inhaler with caution.

Trelegy Ellipta 62.5 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking. Alcohol and other respiratory medications should be used with caution.